- Q1 2024 Aclaris Therapeutics Inc Earnings Call TranscriptMay 07, 2024$1.34 (+2.29%)Earnings
- Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call TranscriptNov 13, 2023
- Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Aclaris Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2023$8.4 (-6.46%)Earnings
- Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Aclaris Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Aclaris Therapeutics Inc R&D Day (Virtual) TranscriptDec 07, 2021
- Aclaris Therapeutics Inc ATI-1777 Clinical Data Call TranscriptJun 08, 2021
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJan 19, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 17, 2020
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q4 2019 Aclaris Therapeutics Inc Earnings Call TranscriptFeb 25, 2020$1.37 (-4.20%)Earnings
- Q3 2019 Aclaris Therapeutics Inc Earnings Call TranscriptNov 07, 2019$1.69 (+4.32%)Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptOct 24, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptSep 27, 2019
- Q2 2019 Aclaris Therapeutics Inc Earnings Call TranscriptAug 08, 2019$0.99 (-2.94%)Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptJul 30, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 26, 2019
- Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study TranscriptJun 17, 2019
- Q1 2019 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2019$6.57 (-1.65%)Earnings
- Q4 2018 Aclaris Therapeutics Inc Earnings Call TranscriptMar 18, 2019Earnings
Aclaris Therapeutics, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Aclaris Therapeutics Announces Investigator-Initiated Trial of ATI-450 for CRS in Hospitalized Patients with COVID-19 Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Kamil Ali-Jackson, Chief Legal Officer of Aclaris.
Thank you, and please go ahead, ma'am.
Thank you, Chris. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing its support of an investigator-initiated Phase IIa, randomized, double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of ATI-450, its oral investigational MK2 inhibitor compound as a potential treatment for cytokine release syndrome in hospitalized patients with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)